Drug Profile
Research programme: p38 MAP kinase inhibitors - Merck
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Quinolizines; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (PO)
- 06 Apr 2010 Preclinical development is ongoing in USA
- 05 Sep 2007 Preclinical trials in Rheumatoid arthritis in USA (PO)